Business Wire

Allvue Expands European Footprint, Names KPMG Luxembourg as Core Implementation Partner

25.11.2025 08:56:00 CET | Business Wire | Press Release

Share

Allvue Systems, LLC (“Allvue”), a leading software technology provider for the private capital markets, today announced an expansion of its current presence in EMEA, naming KPMG Luxembourg as its core implementation partner for all client deliverables for Europe. The strategic collaboration is designed to meet the growing demand from global asset managers leveraging Luxembourg as the premier European fund domicile. By aligning Allvue’s world-class, unified technology platform and solutions with KPMG’s renowned local expertise in private assets, deep regional relationships, and plurilingual delivery capabilities, the partnership offers clients a faster, more effective path to technology adoption.

“Our mission is to make private markets more transparent, efficient, and connected through our AI-powered platform and a strong ecosystem of delivery partners,” said Steven Kilby, Chief Technology Officer at Allvue Systems. “By expanding our presence in Luxembourg with KPMG, clients can now adopt Allvue solutions with confidence, knowing implementation will be delivered at speed by a trusted partner with deep local expertise.”

Fueling Growth in Europe's Fund Capital

Luxembourg is the largest fund domicile in Europe, managing over €5 trillion in assets, and remains a magnet for global private capital managers. This growth, however, comes with increasing regulatory complexity and heightened competition, making seamless technology implementation essential.

This partnership is designed to directly address the challenge of adopting complex technology in this market, which is heightened by local regulatory requirements and linguistic diversity. The collaboration will ensure that new and existing Allvue clients benefit from:

  • Regional knowledge: Access to KPMG Luxembourg’s specialized teams, who possess deep regulatory knowledge and trusted local relationships. Paired with Allvue’s expert knowledge in private markets, this creates a unique ‘best of both worlds’ advantage in Luxembourg.
  • Seamless delivery: Implementation teams capable of delivering solutions in key local languages, including French, English and more, ensuring smooth project management for Luxembourg and European-based managers.
  • Accelerated confidence: The ability to rapidly adopt world-class, API-first technology (including Allvue’s AI Agent Andi) with the backing of a highly recognized regional advisor in KPMG. In addition, by generating sharper, data-driven results, AI lets clients convert insights into tangible business wins.
  • Proven track record: Allvue supports 500+ global clients across the private capital industry. This global expertise ensures that managers in the region benefit from solutions already scaled and trusted by the world's leading firms.

“KPMG Luxembourg's deep regional relationships and standing as a Center of Excellence for fund administration make us one of the region’s most recognized advisors. Supported by our plurilingual teams, who understand the market, we can deliver faster, smoother implementations and results with speed and precision,” said Niels Ozerée, Partner in Advisory at KPMG Luxembourg. “Our combined strength, Allvue’s software solutions coupled with KPMG’s delivery expertise, directly addresses the market's need for delivery excellence across Luxembourg and wider Europe at a time when technology adoption is crucial for competitive advantage.”

EMEA expansion

Allvue is one of the first AI-powered alternative investment software platforms. These innovations, unveiled at Allvue Access, have been designed to make private markets transparent, connected, and efficient by unifying data, automating workflows, surfacing benchmarks, and delivering actionable insights across the entire private investment lifecycle. KPMG Luxembourg is set to become our first official implementation partner within the Luxembourg region, marking a significant milestone in driving growth across EMEA. This partnership is a pivotal step in our global collaboration with KPMG, reinforcing our shared commitment to universal excellence.

About Allvue Systems

Allvue Systems provides actionable insights, benchmarks, and automation through an AI-powered platform that unifies data and streamlines workflows across the private investment lifecycle. With more than $8.5T in assets, 21K funds, and 500 clients managed on Allvue, we help make private markets more transparent, connected, and efficient.

Allvue is purpose-built for alternative investment managers and our integrated suite of software enables firms of all sizes, including private equity, private debt and public credit managers, fund administrators, and banks, to enhance data accuracy and make smarter investment decisions. Headquartered in Miami, Allvue operates across North America, Europe, and India. Visit allvuesystems.com to learn more.

About KPMG Luxembourg

KPMG in Luxembourg is a leading provider of professional services of audit, tax and advisory. KPMG operates in 146 countries and has more than 227,000 professionals working in member firms around the world.

Follow KPMG on: Facebook | X | LinkedIn | YouTube | Instagram | Xing

Disclaimer: The parties hereto are independent contractors. Despite the use of the word “partner” this Press Release does not create or imply an agency, partnership, joint venture or any other form of legal association. Neither Party has the right to bind the other to any agreement with a third party nor to represent itself as an agent, partner or joint venture of the other or to incur any obligation or liability on behalf of the other Party.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251124616747/en/

Contacts

Michelle Wu
Allvue Systems
+1 347-384-9775
press@allvuesystems.com

Babajide Adesesan
Made by Giants
+44 7351869632
allvue@madebygiants.io

Genevieve Feyt
KPMG Luxembourg
+352 22 51 51 2903
genevieve.feyt@kpmg.lu

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye